This is a multicenter, open-label, Phase I dose escalation study of safety, pharmacodynamics, and pharmacokinetics of CG-806 in ascending cohorts (3+3 design) to determine the MTD or recommended dose in patients with relapsed or refractory AML. This is to be followed by a cohort expansion phase at the MTD or recommended dose.
This study is being done to evaluate the safety, tolerability and antitumor activity of oral
CG-806 (luxeptinib) for the treatment of patients with Acute Myeloid Leukemia (except APML),
secondary AML, therapy-related AML, or higher-risk MDS, whose disease has relapsed, is
refractory or who are ineligible for or intolerant of intensive chemotherapy or
Aptose Biosciences Inc.
The following cities have CG-806 clinical trial sites. Please check back often as locations will be updated.
For more information on enrollment in our current clinical trials, please contact us or visit clinicaltrials.gov for location information.
The safety and efficacy of the investigational use of these products have not been determined. There is no guarantee that the investigational use listed will be filed with and/or approved for marketing by a regulatory agency.